For more than 30 years, researchers have identified and quantified genetic and lifestyle factors for Alzheimer’s Disease (AD) and other dementias. Despite extensive research, the fundamental mechanisms behind these neurodegenerative diseases are still not fully understood, and effective management of AD is taking longer than expected.
Eckert & Ziegler Achieves European Approval for Theralugand® – Lutetium-177 Chloride (n.c.a) – Biotech Investments
EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch Eckert & Ziegler Achieves European Approval for Theralugand® – Lutetium-177 Chloride (n.c.a) 27.11.2024 /